Systematic review of health state utility values in metastatic non-small cell lung cancer with a focus on previously treated patients-Reference-Cited by-同舟云学术

Systematic review of health state utility values in metastatic non-small cell lung cancer with a focus on previously treated patients

Published:2018-09-12 Issue:1 Volume:16 Page:
ISSN:1477-7525
Container-title:Health and Quality of Life Outcomes
language:en
Short-container-title:Health Qual Life Outcomes

Author:

Paracha Noman,Abdulla Ahmed,MacGilchrist Katherine S.

Funder

F. Hoffmann-La Roche

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health,General Medicine

Link

http://link.springer.com/content/pdf/10.1186/s12955-018-0994-8.pdf

Reference100 articles.

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.

2. American Cancer Society. What is non-small cell lung cancer? Available at https://www.cancer.org/cancer/non-small-cell-lung-cancer/about/what-is-non-small-cell-lung-cancer.html . Accessed 24 Aug 2017.

3. Edge SB, Byrd DR, Compton CC. AJCC cancer staging handbook. 7th ed. New York, NY: Springer; 2010.

4. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.

5. Tsao AS. Lung carcinoma. Available at http://www.msdmanuals.com/professional/pulmonary-disorders/tumors-of-the-lungs/lung-carcinoma . Accessed 8 Nov 2017.

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. International Cost-Effectiveness Analysis of Durvalumab in Stage III Non–Small Cell Lung Cancer;JAMA Network Open;2024-05-30

2. RETRACTED: Cost-effectiveness of chemotherapy and dostarlimab for advanced or recurrent endometrial cancer;Gynecologic Oncology;2024-04

3. Quality Appraisal in Systematic Literature Reviews of Studies Eliciting Health State Utility Values: Conceptual Considerations;PharmacoEconomics;2024-03-29

4. Osimertinib in the treatment of resected EGFR-mutated non-small cell lung cancer: a cost-effectiveness analysis in the United States;Frontiers in Pharmacology;2024-03-28

5. Exploring the Cost Effectiveness of a Whole-Genome Sequencing-Based Biomarker for Treatment Selection in Patients with Advanced Lung Cancer Ineligible for Targeted Therapy;PharmacoEconomics;2024-01-09